Breaking News
Sort by:
Top Post
Novalis Biotech Invests in Ultra Sensitive Genomics Technology by Rarity Bioscience
Rarity Bioscience announces a new strategic investment from Belgium-based Novalis Biotech. The investment is facilitated […]
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
Freenome, a privately held biotech company, today announced a Series D funding of $300 million. […]
Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19
Sosei Group Corporation (“the Company”; TSE: 4565) today announced it has received grant funding from […]
HypnoVR Raises €4.5 Million to Accelerate the Roll Out of its Digital Therapy Treating Pain and Anxiety
HypnoVR, a market leader in the field of digital therapies to manage pain and stress, […]
Vinehealth Raises $5.5m to Improve the Quality of Life and Survival of Cancer Patients
Today, Vinehealth announces it has raised $5.5m in seed funding. The round was led by […]
Holmusk Announces Closing of Strategic Investment from Healthcare and Life Science Industry Leaders
Holmusk, a leading global data science and digital health company building the world’s largest Real-World […]
PDC*line Pharma Raises €17.5 Million ($20.3M) in Series B2 Financing Round
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable […]
Sixfold Bioscience Completes $10.5M USD (£7.8M GBP) Seed Financing
Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery […]
EverImmune Raises €5M to Enter Clinical Phase in Microbiota Immuno-oncology
EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field […]
Northwest Biotherapeutics Announces $15 Million Financing
Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor […]
Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more